Skip to main content
TipRanks
Go Ultimate75% OFF

Elicera Therapeutics AB (ELIC) Stock Statistics & Valuation Metrics

3 Followers

Total Valuation

Elicera Therapeutics AB has a market cap or net worth of SEK 166.84M. The enterprise value is SEK 84.26M.

Market Cap
SEK 166.84M
Enterprise Value
SEK 84.26M

Share Statistics

Elicera Therapeutics AB has 66,736,374 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
66,736,374
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

Elicera Therapeutics AB’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is -76.81%.

Return on Equity (ROE)
-0.75
Return on Assets (ROA)
-0.63
Return on Invested Capital (ROIC)
-76.81%
Return on Capital Employed (ROCE)
-0.77
Revenue Per Employee
0
Profits Per Employee
-5.80M
Employee Count
3
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Elicera Therapeutics AB is -7.07. Elicera Therapeutics AB’s PEG ratio is 2.30.

PE Ratio
-7.07
PS Ratio
-1129.93
PB Ratio
2.37
Price to FCF
-6.48
Price to Operating Cash Flow
-5.18
PEG Ratio
2.30

Income Statement

In the last 12 months, Elicera Therapeutics AB had revenue of 0 and earned -17.41M in profits. Earnings per share was -0.38.

Revenue
0
Gross Profit
0
Operating Income
-17.94M
Pretax Income
-17.41M
Net Income
-17.41M
EBITDA
-17.40M
Earnings Per Share (EPS)
-0.38

Cash Flow

In the last 12 months, operating cash flow was -25.75M and capital expenditures 0, giving a free cash flow of -25.75M billion.

Operating Cash Flow
-25.75M
Free Cash Flow
-25.75M
Free Cash Flow per Share
-0.48

Dividends & Yields

Elicera Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-15.43%
Earnings Yield
-13.49%

Stock Price Statistics

Beta
0.25
52-Week Price Change
-53.43%
50-Day Moving Average
2.77
200-Day Moving Average
3.46
Relative Strength Index (RSI)
34.76
Average Volume (3m)
249.82K

Important Dates

Elicera Therapeutics AB upcoming earnings date is Nov 27, 2026, TBA (Not Confirmed).

Last Earnings Date
Aug 28, 2026
Next Earnings Date
Nov 27, 2026
Ex-Dividend Date
―

Financial Position

Elicera Therapeutics AB as a current ratio of 6.75, with Debt / Equity ratio of 0.00%

Current Ratio
6.75
Quick Ratio
6.75
Debt to Market Cap
0.00
Net Debt to EBITDA
1.43
Interest Coverage Ratio
-2278.11

Taxes

In the past 12 months, Elicera Therapeutics AB has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Elicera Therapeutics AB EV to EBITDA ratio is -6.03, with an EV/FCF ratio of -4.22.

EV to Sales
-736.26
EV to EBITDA
-6.03
EV to Free Cash Flow
-4.22
EV to Operating Cash Flow
-4.22

Balance Sheet

Elicera Therapeutics AB has SEK 58.13M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 58.13M billion.

Cash & Marketable Securities
SEK 58.13M
Total Debt
SEK 0.00
Net Cash
SEK 58.13M
Net Cash Per Share
SEK 0.87
Tangible Book Value Per Share
SEK 1.05

Margins

Gross margin is 100.00%, with operating margin of 12464.91%, and net profit margin of 12178.95%.

Gross Margin
100.00%
Operating Margin
12464.91%
Pretax Margin
12178.95%
Net Profit Margin
12178.95%
EBITDA Margin
12208.48%
EBIT Margin
12208.48%

Analyst Forecast

The average price target for Elicera Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
14.10%

Scores

Smart Score
―
AI Score
48